Business
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes RUTHERFORD, N.J., Jan.
About this update from Glucotrack, Inc.
[{"type":"text","content":"New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes\nRUTHERFORD, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Ted Williams has been named Vice President of Regulatory Affairs, effective immediately. Mr. Williams has nearly 25 years of experience and a proven track record of successful management of Regulatory Affairs and Quality Assurance for highly complex Class III medical devices including active, long term implantable continuous glucose monitors (“CGM”), drug/device combination products, in-dwelling catheter based endovascular temperature control modules and cardiovascular biopharmaceutical drug development within the 510(k), De Novo, Premarket Approval and Biologics License Application Regulatory pathways. He served as Vice President, Regulatory Affairs/Quality Assurance for Glysens Inc, a technology innovator focused on development of an implantable CGM. Prior to that, his experience includes roles with Therapeutics Inc. and Cardium Therapeutics focusing on oral and injectable drugs, biologics, medical devices and gene therapy. “I am honored to join the Company at this pivotal time as we advance our human clinical trials and create a strategic regulatory program for the Continuous Blood Glucose Monitor (CBGM),” said Mr. Williams. Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack, said: “Mr. Williams brings extensive knowledge and experience in navigating regulatory pathways to Glucotrack, which will be instrumental as we progress development of our CBGM through the Food and Drug Administration and beyond. We are thrilled to welcome him to the team as we work to bring this technology closer to the millions of people living with diabetes.” For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release. About Glucotrack, Inc. Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is c...